speb/financial-data huggingface dataset:
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 433000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 38023000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 38023000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 0.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 5000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 37000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Income: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Income: 1833000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1833000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1833000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1833000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1833000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 4962000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 4962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1833000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -98000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Interest Income: 67000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -159000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -249000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -246000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -417000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 67000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -159000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: 1000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Net PPE: 40308000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 40308000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -7603000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 171000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 46966000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 46966000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 2188000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 2188000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 295000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 295000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 433000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 433000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 511000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 511000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 10962000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 3625000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Normalized Income: 4619870889.53
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 1833000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 11676000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Operating Income: 6134000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Operating Income: 2421000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Operating Revenue: 35128000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 10180000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 401365314.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 401365314.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: -1000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 7196000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 7196000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 794000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 794000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 303000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 303000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -13000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: -3000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: -3000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: -1000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: -1000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 718000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 189000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 4619000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 1818000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Payable: 1304000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 1304000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Properties: 27418000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 27418000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 244000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 244000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 10304000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 10304000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Other Special Charges: -326000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Other Special Charges: -6000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Payables: 4908000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Payables: 4908000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 713000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 713000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 1300000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 1300000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Pretax Income: 6599000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 2405000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 137000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -98000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -35534000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -7603000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 1354000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 1354000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 9425000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2350000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 4326000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 1061000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 61000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 61000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -417000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 1000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 1000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 38820000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 38820000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 35285000000.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 0.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 227000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 1923000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Share Issued: 402536981.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 402536981.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Special Income Charges: 296000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
SYNGENE.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 373000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 47269000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 47269000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 46966000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 46966000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 112870889.53
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Tax Provision: 1637000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 572000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.25
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.24
SYNGENE.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -1153000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Assets: 67959000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 67959000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 47269000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 47269000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Debt: 5779000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 5779000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 47269000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 47269000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Total Expenses: 28994000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 7759000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 20690000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 20690000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 45086000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 45086000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 6726000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 6726000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 84000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 84000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 455000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 455000000.00
SYNGENE.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Treasury Shares Number: 1171667.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 1171667.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Treasury Stock: 53000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 53000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Work In Process: 143000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 143000000.00
SYNGENE.NS balance_sheet (annual, 2025-03-31) — Working Capital: 8909000000.00
SYNGENE.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 8909000000.00
SYNGENE.NS income_statement (annual, 2025-03-31) — Write Off: 30000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 5569000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 8745000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 401388889.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 2.16
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2176000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 1112000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 1112000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 403255814.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 2.15
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — EBIT: 1129000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — EBITDA: 2241000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 6569000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 116000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 116000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Income: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -116000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -116000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 2241000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 867000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Operating Income: 1000000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 8745000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 177000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 1840000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 1013000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2176000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 1112000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 146000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.14
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 7745000000.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
SYNGENE.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 5690000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 9171000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 405405405.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 0.37
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 2294000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 1137000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 1137000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 405405405.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.37
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — EBIT: 403000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — EBITDA: 1540000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 6877000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 119000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 119000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Income: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 150000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -119000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -119000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 2246000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 644200000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Operating Income: 1187000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 9171000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 154000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 1879000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 284000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 2294000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 1137000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -706000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -211800000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 134000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 7984000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -706000000.00
SYNGENE.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -706000000.00
SYNGENE.NS income_statement (annual, 2026-03-31) — +Operating Expense: 21348000000.00
SYNGENE.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 5904000000.00
SYNGENE.NS income_statement (annual, 2026-03-31) — +Total Revenue: 36107000000.00
SYNGENE.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 10365000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 3475000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 3475000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 5088000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 5088000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -27824000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -27824000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 2706000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 2706000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -120000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -120000000.00
SYNGENE.NS income_statement (annual, 2026-03-31) — Amortization: 106000000.00
SYNGENE.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 106000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 5503000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 5503000000.00
SYNGENE.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 401902174.00
SYNGENE.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 3.68
SYNGENE.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 3671000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 12252000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 12252000000.00
SYNGENE.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -3682000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 4490000000.00
SYNGENE.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 4490000000.00
SYNGENE.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 4029000000.00